<DOC>
	<DOCNO>NCT01968499</DOCNO>
	<brief_summary>This registration study aim investigate association pharmacogenetic pharmacokinetic factor clopidogrel low response clinical outcome patient coronary artery disease , provide new pharmacogenetic pharmacokinetic target individualize anti-platelet treatment .</brief_summary>
	<brief_title>Pharmacogenetic Pharmacokinetic Study Clopidogrel</brief_title>
	<detailed_description>Associations Pharmacogenetic Pharmacokinetic Factors With Clopidogrel Low Response Clinical Outcome Patients With Coronary Stent Implantation : Registration Study Published data link clopidogrel non-responsiveness adverse ischaemic event lead suggestion magnitude platelet inhibition clopidogrel monitor individually adjust . This test randomised clinical trial ( ARCTIC , GRAVITAS TRIGGER-PCI ) , despite reduce platelet reactivity , strategy therapy adjustment base platelet function monitoring reduce incidence cardiac ischaemic events1 , indicate pharmacodynamical test monitor anti-platelet treatment fail far . We accordingly perform registration study investigate whether pharmacogenetic pharmacokinetic factor associate clopidogrel low response well clinical outcome , aim provide new target individualize anti-platelet treatment . Inclusion criterion : 1 . Successively recruit patient receive stent implantation ; 2 . Patient age &gt; 18 year ≦80 year old ; 3 . Signed inform consent . Exclusion criterion : 1.None Clinical data collection : 1 . Patients basic characteristic . 2 . Diagnosis complicate disease . 3 . Medical treatment interventional treatment . Methods : Blood sample collect 5th day patient ' take clopidogrel perform genetic test determine light transmittancy aggregation ( LTA ) serum level parent clopidogrel , intermediate active metabolite clopidogrel . LTA re-determined 1 month clopidogrel consumption . Clopidogrel low response define inhibition platelet aggregation ( IPA ) response 5μM ADP 60 % . Clinical follow-up perform 1month , 6month , 1year patient ' include . Major adverse cardiovascular event ( MACE ) set death , non-fatal myocardial infarction ( MI ) , ischemic stroke . Associations pharmacogenetic pharmacokinetic factor clopidogrel low response clinical outcome analyze . Tests : 1 . ADP-induced platelet aggregation : LTA response 5μM ADP . 2 . Arachidonic acid ( AA ) -induced platelet aggregation : LTA response 1mM AA . 3 . Simultaneous detection clopidogrel , 2-oxo-clopidogrel thiol metabolite human plasma high performance liquid chromatography-tandem mass spectrometry ( HPLC-MS/MS ) method . 4 . GWAS scan genotyping ABCB1 , CYP2C19 , paraoxonase 1 ( PON1 ) . Sample size : We plan recruit 1500 patient . Clinical follow-up : 1 month , 6 month , 1 year patient ' include . Major adverse cardiovascular event ( MACE ) : Death , non-fatal MI , ischemic stroke . Minor adverse cardiovascular event : Hospitalization , revascularization , stent thrombosis ( ARC definition ) minor , moderate , major bleeding ( TIMI definition ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Successively recruit patient receive stent implantation ; 2 . Patient age &gt; 18 year ≦80 year old ; 3 . Signed inform consent . 1.None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>coronary stent implantation ; clopidogrel low response</keyword>
</DOC>